Renal Cancer Pipeline Outlook Report 2024

DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Renal Cancer Pipeline Report
• DelveInsight's Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
• The leading Renal Cancer Companies working in the market includes Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Promising Renal Cancer Pipeline Therapies in the various stages of development includes Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
• March 2024: HiberCell Inc. announced a study of Phase 1 clinical trials for HC-7366 and Belzutifan. This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion.
• March 2024: Exelixis announced a study of Phase 1 & 2 clinical trials for zanzalintinib and AB521. The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors.
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab, Cabozantinib, Sunitinib and Ipilimumab. The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
• December 2023: Pfizer announced a study of Phase 3 clinical trials for Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib. This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma.
• December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Request a sample and discover the recent advances in Renal Cancer Treatment Drugs @ Renal Cancer Pipeline Outlook Report- https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Renal Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Renal Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Renal Cancer clinical trial landscape.

Renal Cancer Overview
Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth. Renal cell carcinoma is the most common type of adult kidney cancer. It is responsible for approximately 85% of kidney neoplasms. Renal cell carcinoma may be clinically asymptomatic for the majority of its course.

Find out more about Renal Cancer Treatment Landscape @ Drugs for Renal Cancer Treatment- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Renal Cancer Emerging Drugs Profile
• Atezolizumab : Genentech
• Olaparib: AstraZeneca
• MK-4830 : Merck & Co., Inc
• ALLO-316 : Allogene Therapeutics

Renal Cancer Pipeline Therapeutics Assessment
There are approx. 75+ Renal Cancer companies which are developing the Renal Cancer therapies. The Renal Cancer companies which have their Renal Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Delve Insight's Renal Cancer pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Renal Cancer Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Renal Cancer Pipeline Therapies @ Renal Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Renal Cancer Pipeline Report
• Coverage- Global
• Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.

Dive deep into rich insights for new drugs for Renal Cancer treatment, Visit @ Renal Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Renal Cancer Executive Summary
3. Renal Cancer: Overview
4. Renal Cancer Pipeline Therapeutics
5. Renal Cancer Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Olaparib: AstraZeneca
12. Early Stage Products (Phase I)
13. Allogene Therapeutics: ALLO-316
14. Inactive Products
15. Renal Cancer Companies
16. Renal Cancer Products
17. Renal Cancer Unmet Needs
18. Renal Cancer Market Drivers and Barriers
19. Renal Cancer Future Perspectives and Conclusion
20. Renal Cancer Analyst Views
21. Appendix

For further information on the Renal Cancer pipeline therapeutics, reach out to Renal Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://network-850449.mn.co/posts/54015092
https://janjaonline.mn.co/posts/peripheral-t-cell-lymphoma-market-size-report
https://stayuplate.mn.co/posts/54064250
https://kidzbookzonego.mn.co/posts/54064268
https://unplugfromthematrix.mn.co/posts/54064299
https://smashscore.mn.co/posts/54064368
https://network-70098.mn.co/posts/54064442
https://network-96638.mn.co/posts/54067493
https://network-2813601.mn.co/posts/54067609
https://network-483739.mn.co/posts/54067705
https://network-90246.mn.co/posts/54067789
https://morning-with-members.mn.co/posts/54067991
https://ourownnetwork.mn.co/posts/exploring-the-peripheral-t-cell-lymphoma-market-trends-treatments-and-future-prospects
https://network-2295034.mn.co/posts/understanding-the-dynamics-of-the-peripheral-t-cell-lymphoma-market
https://happilyoga.mn.co/posts/54069560
https://network-90795.mn.co/posts/54069636
https://diecast64.mn.co/posts/54069716
https://network-79939.mn.co/posts/54069751
https://network-5018780.mn.co/posts/understanding-the-dynamics-of-the-peripheral-t-cell-lymphoma-market
https://smart-business-community-network.mn.co/posts/54070391
https://ourclass.mn.co/posts/exploring-the-landscape-of-peripheral-t-cell-lymphoma-market
https://network-89217.mn.co/posts/54074972
https://live-for-less.mn.co/posts/54076556
https://agario-game-org.mn.co/posts/54076639
https://lean-in-bay-area.mn.co/posts/54077460
https://network-6598483.mn.co/posts/54077541
https://thecommunitnetwork.mn.co/posts/54077640
https://marquis-social-community-network.mn.co/posts/54077704
https://clicksharedone.mn.co/posts/understanding-the-dynamics-of-the-peripheral-t-cell-lymphoma-market
https://sirimangalo.mn.co/posts/54078499
https://network-79124.mn.co/posts/54078533
https://work-progress-in-business-thinking.mn.co/posts/54078559
https://network-84269.mn.co/posts/54078586
https://nxgen.mn.co/members/19995548
https://elderassociation.mn.co/posts/54079088

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

This release was published on openPR.